{
  "id": "cluster_3_doc4",
  "content": "Research bulletin from Nevada Health Institute shows 42% of GT-204-19C participants required medication adjustments within first 90 days. Most common side effects included elevated liver enzymes (23%) and neuropathic pain (18%). Study coordinator contact: genetherapy@nhi.nv.gov",
  "metadata": {
    "format": "research_note"
  }
}